Lantern Pharma Inc (LTRN)
6.17
+0.73
(+13.42%)
USD |
NASDAQ |
May 03, 15:04
Lantern Pharma Cash from Financing (TTM): -0.50M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -0.50M |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | -2.182M |
September 30, 2022 | -3.055M |
June 30, 2022 | -3.055M |
March 31, 2022 | -3.055M |
December 31, 2021 | 63.42M |
Date | Value |
---|---|
September 30, 2021 | 64.29M |
June 30, 2021 | 64.19M |
March 31, 2021 | 87.85M |
December 31, 2020 | 23.66M |
September 30, 2020 | 23.67M |
June 30, 2020 | 24.84M |
March 31, 2020 | 1.176M |
December 31, 2019 | 2.920M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-3.055M
Minimum
Mar 2022
87.85M
Maximum
Mar 2021
20.24M
Average
1.176M
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
Eyenovia Inc | 19.79M |
Cassava Sciences Inc | 2.56M |
Alpine Immune Sciences Inc | 165.12M |
Clearside Biomedical Inc | 0.414M |
Poseida Therapeutics Inc | 16.13M |